MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Expectations By $0.09 EPS

MediWound (NASDAQ:MDWD) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.09, FiscalAI reports. MediWound had a negative net margin of 98.43% and a negative return on equity of 62.11%. The business had revenue of $1.87 million during the quarter, compared to the consensus estimate of $2.09 million.

Here are the key takeaways from MediWound’s conference call:

• EscharEx phase 3 VALUE trial is actively enrolling toward a 216‑patient target across ~40 U.S./EU sites with a pre‑specified interim assessment and expected enrollment completion by year‑end 2026, and the company plans a phase 2 diabetic foot ulcer study plus an investigator pressure‑ulcer study in H2 2026 with multiple industry collaborators (e.g., B. Braun).
• The expanded NexoBrid manufacturing facility is operational and boosts production capacity sixfold, with commercial release pending regulatory clearances expected in 2026 and management prioritizing support for burn‑center adoption and national stockpiling/military preparedness.
• 2025 revenue declined to $17.0M (Q4 $1.9M) and operating/adjusted EBITDA losses widened as R&D rose to $14.3M to fund EscharEx, with the shortfall driven primarily by a U.S. government shutdown and lower product sales to Vericel.
• The balance sheet was strengthened to $53.6M in cash following a $30M registered direct offering and warrant exercises, and management reaffirmed multi‑year revenue guidance ($24–26M in 2026; $32–35M in 2027; $50–55M in 2028), while noting these forecasts assume BARDA/DoD support.

MediWound Stock Performance

MDWD traded down $0.46 on Friday, hitting $16.99. The company had a trading volume of 64,269 shares, compared to its average volume of 107,132. The stock has a market capitalization of $217.59 million, a price-to-earnings ratio of -8.94 and a beta of 0.13. The stock has a fifty day moving average price of $17.73 and a 200-day moving average price of $17.87. MediWound has a 12-month low of $14.14 and a 12-month high of $22.50.

Analyst Upgrades and Downgrades

MDWD has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Zacks Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, MediWound currently has a consensus rating of “Hold” and an average target price of $31.67.

Trending Headlines about MediWound

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: Management raised its top‑line outlook — MediWound gave 2026 revenue guidance of $24M–$26M (above the $22.6M consensus) and assigned 2027 revenue guidance of $32M–$35M, signaling expected multi‑year growth as product launches and clinical programs advance. Article Title
• Positive Sentiment: EscharEx Phase III (VALUE) is progressing and the company expanded NexoBrid manufacturing; management expects regulatory approvals in 2026 — these operational updates support the revenue guidance and potential near‑term commercial upside. Article Title
• Neutral Sentiment: Quarterly EPS beat: MDWD reported a loss per share of $0.56, slightly better than the $0.60 consensus (EPS beat can calm investors even though it’s still a loss). Article Title
• Neutral Sentiment: MediWound filed its Form 20‑F for FY2025, providing the latest audited financials and corporate disclosures (routine compliance event). Article Title
• Negative Sentiment: Revenue miss and low current sales: Q4 revenue was $1.87M vs. estimates of $2.09M and full‑year 2025 revenue was $17M — investors may be disappointed by the slow current revenue base despite future guidance. Article Title
• Negative Sentiment: Company remains unprofitable with wide negative margins and negative ROE; cash of ~$54M gives runway but profitability and sustained cash flow are still several quarters/years away, which keeps valuation and near‑term sentiment pressured. Article Title

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP bought a new position in shares of MediWound during the 4th quarter worth approximately $26,000. BNP Paribas Financial Markets grew its holdings in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in shares of MediWound during the 4th quarter valued at $109,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.